Probatebeta
Target

SLC6A4

Sodium-dependent serotonin transporter

As of the edition of 20 October 2026, SLC6A4 (sodium-dependent serotonin transporter, UniProt P31645) has 40 drugs tested at it and 57 companies on the list, 7 on route A and 12 on route B.

Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.

The protein

UniProt
P31645
How well studied
Drug target: an approved drug acts on it
Where it sits in the cell
In more than one place
Solved structures
31
Disease areas
Mental health; Nervous system; Bones, joints and muscles; Urinary and reproductive; Chemically induced; Heart and blood vessels; Nutrition and metabolism; Cancer
Registered trials of its drugs
1,767

Drugs at this target

StatusCount
Marketed26
Active2
Went quiet7
Stopped2
Withdrawn from market3
Total40
DrugStatusFurthest phaseUS protection
EscitalopramMarketedPhase 4Ended 2026
DuloxetineMarketedPhase 4none listed
SertralineMarketedPhase 4none listed
FluoxetineMarketedPhase 4none listed
ParoxetineMarketedPhase 4none listed
VenlafaxineMarketedPhase 4none listed
CitalopramMarketedPhase 4none listed
VortioxetineMarketedPhase 4Ends 2031
MidomafetamineActivePhase 3none listed
DesvenlafaxineMarketedPhase 4Ends 2027
AmitriptylineMarketedPhase 4none listed
FluvoxamineMarketedPhase 4none listed

12 of 40 drugs, the most tested first.

Companies at this target

Where the company standsCompanies
Route A7
Route B12
Engaged13
Undetermined25
Total on the list57
Three companies on route A or B, with the route only
CompanyRoute
GSKRoute B
TakedaRoute B
Bristol Myers SquibbRoute A

The other 54 companies at SLC6A4

In the product

57 companies in all; 54 are not named here, and no score is.

See the 57 companies at SLC6A4, ranked, with the facts behind eachRequest access. Nothing is shown until you do.

More drugs at SLC6A4

Other targets in mental health

Companies holding approvals at SLC6A4